Last reviewed · How we verify
BP1001 plus decitabine
Decitabine is a hypomethylating agent that targets DNA methyltransferase 1 (DNMT1)
Decitabine is a hypomethylating agent that targets DNA methyltransferase 1 (DNMT1) Used for Acute myeloid leukemia (AML).
At a glance
| Generic name | BP1001 plus decitabine |
|---|---|
| Also known as | Liposomal Grb-2, L-Grb-2 |
| Sponsor | Bio-Path Holdings, Inc. |
| Drug class | Hypomethylating agent |
| Target | DNA methyltransferase 1 (DNMT1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Decitabine works by inhibiting the enzyme DNMT1, which is responsible for maintaining DNA methylation patterns. This leads to the reactivation of silenced genes and the induction of apoptosis in cancer cells.
Approved indications
- Acute myeloid leukemia (AML)
Common side effects
- Myelosuppression
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BP1001 plus decitabine CI brief — competitive landscape report
- BP1001 plus decitabine updates RSS · CI watch RSS
- Bio-Path Holdings, Inc. portfolio CI